fda warning letter semaglutide october 2025 The U.S. Food and Drug Administration (FDA) has issued a to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications September 8, 2025: FDA launches

However, approximately 30% of patients do not respond well to medication, and many responders still show limited improvement in academic performance and social functioning

Several studies have found this anaphylaxis-like reaction to occur more often in people given intravenous acetylcysteine despite serum levels of paracetamol not high enough to be considered toxic

This dual mechanism enhances weight loss but has more profound effects on gastric emptying

Although some emerging research suggests that GLP-1RAs might reduce binge-eating episodes, there is not yet enough evidence to support their use specifically for treating binge-eating disorder (BED) and its associated psychopathology

If so, you'll receive an email from OLA Digital Health to schedule your appointment